Clinical Trial Update: Study Evaluating Inhibitor Specificity in Hemophilia A [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating inhibitor specificity in Hemophilia A has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Phase 4 | Status: WITHDRAWN